Allogene Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 7, 2024

ALLO$0.93-12.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2024	2023	2024	2023
Collaboration revenue - related party	$—	$22	$22	$74
Operating expenses:
Research and development	44,713	45,977	147,327	188,253
General and administrative	16,333	17,041	49,687	54,449
Impairment of long-lived assets	10,728	—	15,717	—
Total operating expenses	71,774	63,018	212,731	242,702
Loss from operations	(71,774)	(62,996)	(212,709)	(242,628)
Other income (expense), net:
Interest and other income, net	6,705	6,205	17,126	12,042
Interest expense	(100)	—	(100)	—
Other income and (expense), net	(1,124)	(5,496)	(1,968)	(10,901)
Total other income (expense), net	5,481	709	15,058	1,141
Net loss	(66,293)	(62,287)	(197,651)	(241,487)
Other comprehensive loss:
Net unrealized gain on available-for-sale investments	937	1,440	1,112	7,515
Net comprehensive loss	$(65,356)	$(60,847)	$(196,539)	$(233,972)
Net loss per share, basic and diluted	$(0.32)	$(0.37)	$(1.04)	$(1.58)
Weighted-average number of shares used in computing net loss per share, basic and diluted	209,188,551	167,649,010	189,519,897	153,087,449

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.